Premium
Antidepressant‐Like Activity of Agomelatine in the Mouse Unpredictable Chronic Mild Stress Model
Author(s) -
Mutlu Oguz,
Gumuslu Esen,
Ulak Guner,
Celikyurt Ipek Komsuoglu,
Akar Furuzan,
Bektas Emine,
Demirtas Tugce,
Kır Hale Maral,
Musul Mahmut Mert,
Erden Faruk
Publication year - 2013
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21064
Subject(s) - agomelatine , fluoxetine , melatonin , behavioural despair test , agonist , tail suspension test , endocrinology , medicine , adrenocorticotropic hormone , antidepressant , pharmacology , imipramine , receptor , hormone , psychology , hippocampus , serotonin , alternative medicine , pathology
Preclinical ResearchThe present study was undertaken to investigate whether chronic agomelatine treatment which acts as an agonist of melatonergic MT 1 and MT 2 receptors would block unpredictable chronic mild stress ( UCMS )‐induced depression‐like behavior in mice as compared with fluoxetine and melatonin. Male inbred BALB /c mice were treated with agomelatine (10 mg/kg i.p.), melatonin (10 mg/kg ip), fluoxetine (15 mg/kg ip), or vehicle for 5 weeks. All compounds tested blocked the stress‐induced deficit in coat state during the UCMS procedure, increased total latency of grooming in the splash test, decreased attack frequency in the resident/intruder test, and reduced immobility time in the tail suspension and forced swimming tests. All compounds also reduced the levels of plasma adrenocorticotropic hormone, interleukin 6, and tumor necrosis factor‐alpha in stressed mice. The results of this study indicate that agomelatine, which has a novel mode of action, can be as effective as fluoxetine for the treatment of depression.